Shopping Cart
- Remove All
Your shopping cart is currently empty
KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 mg | Inquiry | Backorder | |
| 500 mg | Inquiry | Backorder |
| Description | KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine. |
| In vitro | The KRAS G13D peptide (25 mer) is encoded by an immunomodulatory therapeutic mRNA, which can serve in the development of a KRAS vaccine [1]. |
| Synonyms | KRAS G13D peptide, 25 mer |
| Molecular Weight | 2634.13 |
| Formula | C118H201N29O36S |
| Cas No. | 145019-94-9 |
| Relative Density. | 1.257 g/cm3 (Predicted) |
| Sequence | Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-Gly-Asp-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-Leu-Ile-Gln |
| Sequence Short | MTEYKLVVVGAGDVGKSALTIQLIQ |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.